These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463 [Abstract] [Full Text] [Related]
24. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders]. Bettini R, Marzetta K, Miglioranza A, Redaelli S, Maino C, Maffiolini A, Gorini M. Recenti Prog Med; 2003 Nov; 94(7-8):314-20. PubMed ID: 12868237 [Abstract] [Full Text] [Related]
26. Endomitotic index of megakaryocytes measured by flow cytometry helps to diagnose hematological disorders with abnormal platelet counts. Baatout S, Chatelain B, Staquet P, Symann M, Chatelain C. Anticancer Res; 1998 Nov; 18(5A):3347-53. PubMed ID: 9858907 [Abstract] [Full Text] [Related]
27. Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification. Barbui T, Thiele J, Kvasnicka HM, Carobbio A, Vannucchi AM, Tefferi A. Leukemia; 2014 Oct; 28(10):2092-4. PubMed ID: 24888272 [No Abstract] [Full Text] [Related]
31. Comparison of four serum-free, cytokine-free media for analysis of endogenous erythroid colony growth in polycythemia vera and essential thrombocythemia. Dobo I, Mossuz P, Campos L, Girodon F, Allégraud A, Latger-Cannard V, Boiret N, Pineau D, Wunder E, Zandecki M, Praloran V, Hermouet S. Hematol J; 2001 Oct; 2(6):396-403. PubMed ID: 11920280 [Abstract] [Full Text] [Related]
32. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Murphy S. Semin Hematol; 1999 Jan; 36(1 Suppl 2):9-13. PubMed ID: 9930551 [Abstract] [Full Text] [Related]
33. High red blood cell distribution width might predict thrombosis in essential thrombocythemia and polycythemia vera. Krečak I, Krečak F, Gverić-Krečak V. Blood Cells Mol Dis; 2020 Feb; 80():102368. PubMed ID: 31669934 [No Abstract] [Full Text] [Related]
34. Glycated hemoglobin (HbA1c) and thrombotic risk in polycythemia vera and essential thrombocythemia. Krecak I, Lekovic D, Grohovac D, Sabljic A, Holik H, Zekanovic I, Moric Peric M, Galusic D, Perisa V, Krecak F, Skelin M, Lucijanic M. Leuk Lymphoma; 2024 May; 65(5):688-691. PubMed ID: 38248137 [No Abstract] [Full Text] [Related]
35. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, van Vliet HH. Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481 [Abstract] [Full Text] [Related]
36. Current evaluation of the clinical, diagnostic, and therapeutic usefulness of prv-1 and c-mpl markers in polycythemia vera and essential thrombocythemia. Pahl HL. Clin Adv Hematol Oncol; 2004 Apr; 2(4):202, 204. PubMed ID: 16163180 [No Abstract] [Full Text] [Related]